Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, November 11, 2019
Sygnature Discovery has added in-house high-throughput screening to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
read more
Monday, November 06, 2023
Sygnature Discovery has incorporated an Azenta compound management storage system into its capabilities, enabling the storage of customer libraries as well. High-fidelity hit finding is a crucial initial step in successful drug discovery projects, ...
read more
Wednesday, January 19, 2022
In a broad career, Dr Woler has held multiple key roles in the sector, including CEO at Roche France, Executive Chairman for Europe at SmithKline Beecham PLC, and CEO at Cadus Pharmaceutical in the US.
read more
Sygnature Discovery has established a new office presence in South San Francisco’s biotech hub at Oyster Point, where it can better serve current and future clients on the US west coast.
read more
Sygnature Discovery announced the set-up of a state-of-the-art Early Candidate Developability Screening Group. The new service line expands the company’s portfolio into formal preclinical drug development. A new world-class facility with ...
read more
Tuesday, November 27, 2018
Sygnature Discovery is continuing the expansion of its operations with the opening of its first US office, located in Harvard Square, Cambridge, Massachusetts.
read more
Monday, February 22, 2021
Sygnature Discovery has begun expanding into new laboratories at Bruntwood SciTech’s Alderley Park.
read more
Sygnature Discovery announced the completion of a major enhancement to its high-throughput chemistry (HTC) capabilities and laboratory infrastructure following a £1 million investment.
read more
Integrated drug discovery and pre-clinical solutions provider, Sygnature Discovery, has appointed Dr. David Lustig to the role of Vice President Business Development - United States.
read more
Sygnature Discovery has announced the appointment of Kieron Hall as its new Chief Commercial Officer (CCO) and Board member.
read more
Sygnature Discovery has announced the appointment of Dr. Paul Overton as Senior VP of Business Development.
read more
Wednesday, January 15, 2020
Sygnature Discovery has further strengthened its DMPK (drug metabolism and pharmacokinetics) capabilities, with the addition of new senior scientists to the management team.
read more
OpenEye Scientific and Sygnature Discovery announced the adoption of OpenEye's Orion platform to power Sygnature's computational efforts in molecular design drug discovery solutions.
read more
Thursday, October 01, 2020
Sygnature Discovery has expanded its DMPK capabilities with the acquisition of XenoGesis.
read more
Sygnature Discovery has acquired Peak Proteins Ltd. Following an extensive partnership between the two companies, this deal will enable seamless integration of protein production and related structure determination projects within Sygnature. ...
read more